Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1889 1
1947 2
1948 1
1949 3
1950 1
1951 1
1952 1
1953 2
1955 1
1956 1
1957 2
1959 1
1961 1
1962 2
1963 2
1964 1
1966 1
1967 2
1968 1
1969 3
1970 4
1971 8
1972 5
1973 8
1974 11
1975 11
1976 13
1977 8
1978 6
1979 5
1980 6
1981 6
1982 11
1983 5
1984 7
1985 10
1986 17
1987 20
1988 16
1989 20
1990 21
1991 23
1992 32
1993 14
1994 18
1995 21
1996 24
1997 25
1998 22
1999 49
2000 36
2001 53
2002 63
2003 56
2004 58
2005 75
2006 69
2007 84
2008 68
2009 77
2010 82
2011 87
2012 139
2013 158
2014 177
2015 213
2016 222
2017 236
2018 280
2019 287
2020 350
2021 402
2022 411
2023 334
2024 120

Text availability

Article attribute

Article type

Publication date

Search Results

4,189 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Furbe
Page 1
Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Heo YA. Heo YA. Drugs. 2021 Aug;81(12):1411-1422. doi: 10.1007/s40265-021-01562-6. Epub 2021 Aug 3. Drugs. 2021. PMID: 34342835 Free PMC article. Review.
A step-up treatment approach combining an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a long-acting beta(2)-agonist (LABA) may provide clinical benefits in patients with COPD whose disease is inadequately controlled by dual therapies (ICS/L …
A step-up treatment approach combining an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a long-acting …
Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies.
Calzetta L, Ritondo BL, de Marco P, Cazzola M, Rogliani P. Calzetta L, et al. Expert Rev Respir Med. 2021 Jan;15(1):143-152. doi: 10.1080/17476348.2020.1816830. Epub 2020 Sep 14. Expert Rev Respir Med. 2021. PMID: 32856967
The weighted efficacy/safety profile resulting from SUCRA provided the following ranking in patients with low eosinophil count: ICS/LABA/LAMA>LABA/LAMAICS/LABA; whereas in patients with high eosinophil count the ranking was as follows: ICS/LABA/LAMA>LABA/LA …
The weighted efficacy/safety profile resulting from SUCRA provided the following ranking in patients with low eosinophil count: ICS/LABA/ …
Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.
Yang M, Li Y, Jiang Y, Guo S, He JQ, Sin DD. Yang M, et al. Eur Respir J. 2023 Feb 9;61(2):2200302. doi: 10.1183/13993003.00302-2022. Print 2023 Feb. Eur Respir J. 2023. PMID: 36137586
METHODS: Two reviewers independently searched Embase, PubMed and Cochrane Library to identify relevant RCTs of LAMA/LABA or LABA/LAMA/inhaled corticosteroids (ICS) for the management of patients with COPD that reported on cardiovascular end-points. ...CONCLUSION: Co …
METHODS: Two reviewers independently searched Embase, PubMed and Cochrane Library to identify relevant RCTs of LAMA/LABA or LABA/L …
Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
Feldman WB, Avorn J, Kesselheim AS, Gagne JJ. Feldman WB, et al. JAMA Intern Med. 2023 Jul 1;183(7):685-695. doi: 10.1001/jamainternmed.2023.1245. JAMA Intern Med. 2023. PMID: 37213116
However, data from randomized clinical trials comparing these combination inhalers (LAMA-LABAs vs ICS-LABAs) have been conflicting and raised concerns of generalizability. ...These findings were robust across a range of prespecified subgroup and sensitivity analyses. CONCL …
However, data from randomized clinical trials comparing these combination inhalers (LAMA-LABAs vs ICS-LABAs) have been conflicting an …
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.
Fukuda N, Horita N, Kaneko A, Goto A, Kaneko T, Ota E, Kew KM. Fukuda N, et al. Cochrane Database Syst Rev. 2023 Jun 5;6(6):CD012066. doi: 10.1002/14651858.CD012066.pub3. Cochrane Database Syst Rev. 2023. PMID: 37276335 Review.
However, updated international guidance recommends a LAMA plus a LABA (LAMA+LABA). This systematic review is an update of a Cochrane Review first published in 2017. ...There is little to no difference between LAMA+LABA and LAMA+ICS in the odds of havin …
However, updated international guidance recommends a LAMA plus a LABA (LAMA+LABA). This systematic review is an update of a Co …
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, Duarte M, Compton C, Vogelmeier CF, Halpin DMG. Ismaila AS, et al. Adv Ther. 2022 Nov;39(11):4961-5010. doi: 10.1007/s12325-022-02234-x. Epub 2022 Jul 20. Adv Ther. 2022. PMID: 35857184 Free PMC article.
There are two different types of bronchodilators, namely long-acting muscarinic antagonists (LAMAs) and long-acting beta(2)-agonists (LABAs), which can be used on their own or combined (LAMA/LABAs). Only a few clinical trials have compared different LAMA/LABA combin …
There are two different types of bronchodilators, namely long-acting muscarinic antagonists (LAMAs) and long-acting beta(2)-agonists (LABAs) …
LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations.
Miravitlles M, Kawayama T, Dreher M. Miravitlles M, et al. J Clin Med. 2022 Nov 8;11(22):6623. doi: 10.3390/jcm11226623. J Clin Med. 2022. PMID: 36431099 Free PMC article. Review.
The recommendations for LABA/LAMA are broader in the American Thoracic Society treatment guidelines, which strongly recommend LABA/LAMA combination therapy over LAMA or LABA monotherapy in patients with COPD and dyspnea or exercise intolerance. ...This articl …
The recommendations for LABA/LAMA are broader in the American Thoracic Society treatment guidelines, which strongly recommend LABA/ …
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B. Vanfleteren L, et al. Int J Chron Obstruct Pulmon Dis. 2018 Dec 12;13:3971-3981. doi: 10.2147/COPD.S185975. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 30587953 Free PMC article. Review.
Recently, two "fixed triple" single-inhaler combinations of an inhaled corticosteroid (ICS), a long-acting beta(2)-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have become available for patients with COPD. This review presents the clinical evidence that l …
Recently, two "fixed triple" single-inhaler combinations of an inhaled corticosteroid (ICS), a long-acting beta(2)-agonist (LABA), and a lon …
Stepwise management of COPD: What is next after bronchodilation?
Miravitlles M, Matsunaga K, Dreher M. Miravitlles M, et al. Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231208630. doi: 10.1177/17534666231208630. Ther Adv Respir Dis. 2023. PMID: 37936381 Free PMC article. Review.
In this narrative review, we describe global and country-specific guideline recommendations from Germany, Spain, and Japan and compare these with real-world data on LABA/LAMA and ICS use in clinical practice. We also provide a clinical guide to the use of add-on therapies …
In this narrative review, we describe global and country-specific guideline recommendations from Germany, Spain, and Japan and compare these …
Benefits of LAMA in patients with asthma-COPD overlap: A systematic review and meta-analysis.
Qin J, Wang G, Han D. Qin J, et al. Clin Immunol. 2022 Apr;237:108986. doi: 10.1016/j.clim.2022.108986. Epub 2022 Mar 25. Clin Immunol. 2022. PMID: 35346865 Review.
Randomized controlled trials (RCTs) on treatment of ACO with LAMA, compared with placebo or blank, were reviewed. RESULTS: Six RCTs (enrolling 1151 participants) met the inclusion criteria. ...CONCLUSIONS: The addition of LAMA significantly improved lung function an …
Randomized controlled trials (RCTs) on treatment of ACO with LAMA, compared with placebo or blank, were reviewed. RESULTS: Six RCTs ( …
4,189 results